The Iron Chelator and Anticancer Agent Dp44mT Relieves Allergic Inflammation in Mice With Allergic Rhinitis

Area of Science:

• Immunology
• Pharmacology
• Allergy Research

Background:

• Previous research indicated the anti-inflammatory properties of Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) in human mast cells.
• The in vivo anti-inflammatory efficacy of Dp44mT, particularly in allergic rhinitis models, remained largely uninvestigated.

Purpose of the Study:

• To evaluate the therapeutic potential of Dp44mT in mitigating the clinical manifestations of ovalbumin (OVA)-induced allergic rhinitis (AR) in a murine model.
• To elucidate the underlying mechanisms by which Dp44mT exerts its anti-inflammatory effects in the context of AR.

Main Methods:

• Ovalbumin (OVA)-induced allergic rhinitis (AR) was established in mice.
• Mice were treated with Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT).
• Clinical symptoms, serum cytokine/chemokine levels, immunoglobulin E (IgE), histamine, and inflammatory cell infiltration in intranasal tissues were assessed.

Main Results:

• Dp44mT administration significantly decreased clinical signs of AR, including reduced rubbing behavior.
• Serum levels of histamine, IgE, IL-1β, TSLP, and TNF-α were significantly suppressed by Dp44mT.
• Dp44mT modulated T helper cell responses by increasing interferon-γ (Th1) and decreasing IL-4, IL-5, and IL-13 (Th2) cytokines, while also reducing intranasal inflammatory mediators and cell infiltration.

Conclusions:

• Di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone (Dp44mT) demonstrates significant in vivo anti-inflammatory effects against allergic rhinitis in a mouse model.
• Dp44mT alleviates AR symptoms by suppressing key inflammatory cytokines, chemokines, and cellular infiltration.
• These findings suggest Dp44mT holds potential as a therapeutic agent for allergic rhinitis and related inflammatory conditions.